Featured Research

from universities, journals, and other organizations

Biodegradable Gel Being Studied As Treatment For Esophageal Cancer

Date:
April 20, 2009
Source:
Rush University Medical Center
Summary:
Gastroenterologists are studying the safety and efficacy of a new system for delivering chemotherapy for patients with esophageal cancer, a rare, but deadly disease that attacks the throat. The unique drug therapy delivers a highly concentrated dose of chemotherapy injected directly on to the hard-to-reach tumors in the esophagus nonsurgically. Researchers are trying to determine if the gel treatment can reduce the size of the cancerous tumors.

Gastroenterologists at Rush University Medical Center are studying the safety and efficacy of a new system for delivering chemotherapy for patients with esophageal cancer, a rare, but deadly disease that attacks the throat. The unique drug therapy delivers a highly concentrated dose of chemotherapy injected directly on to the hard-to-reach tumors in the esophagus non-surgically.

Researchers at Rush are trying to determine if the gel treatment can reduce the size of the cancerous tumors.

Patients diagnosed with esophageal cancer are usually diagnosed at very advanced stages and not only have to undergo chemoradiation therapy, but may also have an esophagectomy, which is a surgical procedure to remove a part of or the entire esophagus.

"Patients with esophageal cancer have very few treatment options and life expectancy can be less than two years from first diagnosis," said Dr. Sohrab Mobarhan, principal investigator of the study and clinical director of the Coleman Foundation Comprehensive Clinic for Gastrointestinal Cancers at Rush. "This also could potentially be a viable treatment option for patients who have inoperable tumors located in their esophagus."

The investigational drug, called OncoGel, is made of two major components, the ReGel drug delivery system, which is a gel made up of ingredients used in biodegradable stitches, and paxclitaxel, a well established, FDA-approved anti-cancer chemotherapy agent. Patients receive a one-time injection of OncoGel during an endoscopy.

"In pilot studies, OncoGel has been shown to continuously release paclitaxel, which is the chemotherapy agent, in concentrated doses at a higher magnitude than in just delivering it through the blood for up to six weeks," said Mobarhan.

Esophageal cancer can develop when stomach acid backs up into the lower esophagus, in some cases damaging cells in the inner layer of the esophagus. This abnormal cellular change is known as Barrett's esophagus. A person could ultimately develop cancer of the esophagus as a result of developing Barrett's.

"Because the symptoms do not seem unusual, the disease can go unnoticed and ignored for long periods of time," said Mobarhan. "A chronic cough, sore throat, indigestion and acid reflux are some of the symptoms that can mask the disease. The lesions that form into cancerous tumors can cause the opening of the esophagus to narrow to nearly half its usual width and make it difficult to swallow."

Data indicates that only 16,000 new cases of esophageal cancer are reported in the U.S. in 2008 and more than 14,000 people – almost 90 percent – died from the disease.

In an earlier phase of the study of OncoGel in patients with late stage inoperable esophageal cancer, 70 percent of patients had a reduction in tumor volume when OncoGel was used in combination with radiotherapy. In addition, after treatment, biopsy samples did not contain tumor cells in almost 40 percent of patients.

OncoGel is pending approval by the U.S. Food and Drug Administration (FDA). Patients enrolled in the randomized trial at Rush will receive either a single injection of OncoGel as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation therapy or chemoradiation therapy alone. Participants also may undergo surgical resection (esophagectomy) as part of standard care.


Story Source:

The above story is based on materials provided by Rush University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush University Medical Center. "Biodegradable Gel Being Studied As Treatment For Esophageal Cancer." ScienceDaily. ScienceDaily, 20 April 2009. <www.sciencedaily.com/releases/2009/04/090415162651.htm>.
Rush University Medical Center. (2009, April 20). Biodegradable Gel Being Studied As Treatment For Esophageal Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/04/090415162651.htm
Rush University Medical Center. "Biodegradable Gel Being Studied As Treatment For Esophageal Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/04/090415162651.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins